Breakthroughs in Gene Therapy Offer Promise for Inherited Retinal Diseases
Recent announcements from the U.S. Food and Drug Administration (FDA) signal significant progress in the development of gene therapies for inherited retinal diseases (IRDs). Beacon Therapeutics has received a Regenerative Medicine Advanced Therapy (RMAT) designation for its X-linked retinitis pigmentosa (XLRP) gene therapy, laru-zova, while SpliceBio has secured Investigational New Drug (IND) clearance for its Stargardt disease gene therapy, SB-007. These milestones represent crucial steps forward, bringing new hope to patients and families affected by these debilitating conditions.
For patients living with IRDs, these developments are particularly meaningful. Inherited retinal diseases, such as XLRP and Stargardt disease, are genetic conditions that lead to progressive vision loss and, often, blindness. Currently, effective treatments are limited, making the advancement of gene therapies a critical area of research.
Expedited Pathway for XLRP Treatment
Beacon Therapeutics' gene therapy, laru-zova (also known as laruparetigene zovaparvovec), has been granted RMAT designation by the FDA for the treatment of XLRP. XLRP is a severe form of retinitis pigmentosa predominantly affecting males, caused by mutations in the RPGR gene, and can lead to legal blindness by middle age. The RMAT designation is designed to expedite the development and review of regenerative medicine therapies that show the potential to address serious or life-threatening conditions with unmet medical needs.
This designation was based on promising preliminary clinical evidence from the Phase 2 DAWN and SKYLINE trials, which evaluated the therapy's efficacy, safety, and tolerability in patients with RPGR-mutated XLRP. The RMAT status offers benefits such as enhanced communication with the FDA and opportunities for accelerated approval based on surrogate or intermediate endpoints. Laru-zova is an adeno-associated virus (AAV) vector-based gene therapy delivered subretinally, designed to provide full-length functioning RPGR protein to target the genetic root cause of XLRP.
Advancing Stargardt Disease Gene Therapy
In parallel, SpliceBio has received FDA clearance for its Investigational New Drug (IND) application for SB-007, a gene therapy aimed at treating Stargardt disease (SD). Stargardt disease is the most common form of juvenile macular degeneration, characterized by progressive central vision loss due to mutations in the ABCA4 gene. There is currently no FDA-approved treatment for Stargardt disease.
IND clearance is a critical regulatory milestone that allows a new experimental therapy to be tested in human clinical trials, confirming that preclinical data demonstrates sufficient safety. SpliceBio's SB-007 is particularly notable as it is the first-ever IND clearance for a protein splicing gene therapy. The ABCA4 gene is too large to be delivered by standard AAV vectors. SB-007 addresses this by using a dual AAV vector system to deliver the ABCA4 gene in two halves, which then use protein splicing to create a full-length, functional ABCA4 protein within retinal cells.
The Phase 1/2 ASTRA study for SB-007 is expected to begin in the first half of 2025, evaluating the safety and efficacy of a single subretinal dose in Stargardt patients. This trial is supported by an ongoing natural history study, POLARIS, which aims to refine patient eligibility and outcome measures.
What These Milestones Mean for the Future of IRD Treatment
These regulatory advancements underscore the growing momentum in gene therapy research for IRDs. The RMAT designation for XLRP's laru-zova could significantly accelerate its path to market, potentially offering a much-needed treatment option sooner. Similarly, the IND clearance for SpliceBio's SB-007 opens the door for clinical trials, exploring an innovative protein splicing approach for Stargardt disease, a condition that has long awaited effective therapies.
The progress in both XLRP and Stargardt disease highlights the scientific community's dedication to tackling the genetic root causes of these blinding conditions. As these therapies move through clinical development, they hold the potential to not only slow or halt vision loss but also significantly improve the quality of life for countless individuals and their families. The coming years will be crucial in observing the outcomes of these trials and bringing these promising treatments closer to patients.